254 related articles for article (PubMed ID: 29843122)
21. Hsa-let-7b inhibits cell proliferation by targeting PLK1 in HCC.
He Z; Deng W; Jiang B; Liu S; Tang M; Liu Y; Zhang J
Gene; 2018 Oct; 673():46-55. PubMed ID: 29913237
[TBL] [Abstract][Full Text] [Related]
22. Clinical and prognostic value of chaperonin containing T-complex 1 subunit 3 in hepatocellular carcinoma: A Study based on microarray and RNA-sequencing with 4272 cases.
Hou JY; Wu HY; He RQ; Lin P; Dang YW; Chen G
Pathol Res Pract; 2019 Jan; 215(1):177-194. PubMed ID: 30473171
[TBL] [Abstract][Full Text] [Related]
23. Expression of serum miR-218 in hepatocellular carcinoma and its prognostic significance.
Yang L; Xu Q; Xie H; Gu G; Jiang J
Clin Transl Oncol; 2016 Aug; 18(8):841-7. PubMed ID: 26586116
[TBL] [Abstract][Full Text] [Related]
24. Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma.
Meng X; Wang L; Zhu B; Zhang J; Guo S; Li Q; Zhang T; Zheng Z; Wu G; Zhao Y
Biomed Res Int; 2020; 2020():8657468. PubMed ID: 32462022
[TBL] [Abstract][Full Text] [Related]
25. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
[TBL] [Abstract][Full Text] [Related]
26. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Zhang Z; Zhang G; Kong C
Urol Oncol; 2013 Oct; 31(7):1222-30. PubMed ID: 22192978
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma.
Cheng MW; Wang BC; Weng ZQ; Zhu XW
Acta Histochem; 2012 Sep; 114(5):503-9. PubMed ID: 22000864
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of liver kinase B1 predicts poor prognosis in hepatocellular carcinoma.
Tan X; Liao Z; Liang H; Chen X; Zhang B; Chu L
Int J Oncol; 2018 Nov; 53(5):1913-1926. PubMed ID: 30226588
[TBL] [Abstract][Full Text] [Related]
29. Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma.
Kanaji S; Saito H; Tsujitani S; Matsumoto S; Tatebe S; Kondo A; Ozaki M; Ito H; Ikeguchi M
Oncology; 2006; 70(2):126-33. PubMed ID: 16645325
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.
Tang Q; Hu G; Sang Y; Chen Y; Wei G; Zhu M; Chen M; Li S; Liu R; Peng Z
Clin Transl Med; 2024 May; 14(5):e1703. PubMed ID: 38769666
[TBL] [Abstract][Full Text] [Related]
31. Identification of Potential Prognostic Long Non-Coding RNA Biomarkers for Predicting Survival in Patients with Hepatocellular Carcinoma.
Liao X; Yang C; Huang R; Han C; Yu T; Huang K; Liu X; Yu L; Zhu G; Su H; Wang X; Qin W; Deng J; Zeng X; Ye X; Peng T
Cell Physiol Biochem; 2018; 48(5):1854-1869. PubMed ID: 30092592
[TBL] [Abstract][Full Text] [Related]
32. SUMO-Activating Enzyme Subunit 1 (SAE1) Is a Promising Diagnostic Cancer Metabolism Biomarker of Hepatocellular Carcinoma.
Ong JR; Bamodu OA; Khang NV; Lin YK; Yeh CT; Lee WH; Cherng YG
Cells; 2021 Jan; 10(1):. PubMed ID: 33477333
[TBL] [Abstract][Full Text] [Related]
33. RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation.
Bouhlal H; Ouled-Haddou H; Debuysscher V; Singh AR; Ossart C; Reignier A; Hocini H; Fouquet G; Al Baghami M; Eugenio MS; Nguyen-Khac E; Regimbeau JM; Marcq I
Oncotarget; 2016 Mar; 7(9):9832-43. PubMed ID: 26799423
[TBL] [Abstract][Full Text] [Related]
34. PLK1/NF-κB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression.
Tian L; Yao K; Liu K; Han B; Dong H; Zhao W; Jiang W; Qiu F; Qu L; Wu Z; Zhou B; Zhong M; Zhao J; Qiu X; Zhong L; Guo X; Shi T; Hong X; Lu S
Oncogene; 2020 Apr; 39(15):3145-3162. PubMed ID: 32060423
[TBL] [Abstract][Full Text] [Related]
35. [Expression of checkpoint kinase 1 and polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach].
Yao H; Yang Z; Li Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Oct; 35(10):1080-4. PubMed ID: 21051833
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
[TBL] [Abstract][Full Text] [Related]
37. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression.
Petrelli A; Perra A; Schernhuber K; Cargnelutti M; Salvi A; Migliore C; Ghiso E; Benetti A; Barlati S; Ledda-Columbano GM; Portolani N; De Petro G; Columbano A; Giordano S
Oncogene; 2012 Oct; 31(42):4517-26. PubMed ID: 22249248
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic and prognostic value of WNT family gene expression in hepatitis B virus‑related hepatocellular carcinoma.
Han Q; Wang X; Liao X; Han C; Yu T; Yang C; Li G; Han B; Huang K; Zhu G; Liu Z; Zhou X; Su H; Shang L; Gong Y; Song X; Peng T; Ye X
Oncol Rep; 2019 Sep; 42(3):895-910. PubMed ID: 31322232
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
[TBL] [Abstract][Full Text] [Related]
40. An Integrative "Omics" Approach, for Identification of Bona Fides PLK1 Associated Biomarker in Esophageal Adenocarcinoma.
Bibi N; Rashid S; Nicholson J; Malloy M; O'Neill R; Blake D; Hupp T
Curr Cancer Drug Targets; 2019; 19(9):742-755. PubMed ID: 30747067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
